All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Join our
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
At the ESH 7th Translational Research Conference:
Multiple Myeloma
with Martin Kaiser, Mohamad Mohty, and Rakesh Popat
Saturday, October 5, 2024 | 09:10-10:10 CEST
Register nowThis independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma hub is an independent medical education platform, sponsored by Sanofi, Bristol Myers Squibb, GSK and Roche, and supported through a grant from Janssen Biotech, Inc. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bispecific antibodies (bsAbs) are a form of T-cell engaging immunotherapy that targets specific surface antigens on myeloma cells as well as the patient’s own T cells, causing direct T-cell activation and tumor cell death. The efficacy rates associated with these agents are markedly high; however, they are also associated with significant adverse events and toxicity.1
Here, we summarize a presentation by Einsele1 delivered at the International Myeloma Society (IMS) 5th Immune Effector Cell Workshop 2024 on novel bsAbs in multiple myeloma (MM) and how the unique characteristics (Figure 1) of these drugs may help overcome the challenges associated with bsAb treatment.
Figure 1. Structures of linvoseltamab, ABBV-383, alnuctamab, and cevostamab*
BCMA, B-cell maturation antigen; FcRH5, Fc receptor-homolog 5.
*Adapted from Einsele.1 Created with BioRender.com.
Key learnings |
---|
|
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox